Qiagen

What Qiagen does

Qiagen N.V. is a Netherlands-incorporated molecular diagnostics and life sciences tools company that provides sample preparation technologies, automated instrument platforms, consumables, and bioinformatics for clinical diagnostics, pharmaceutical R&D, and academic research laboratories worldwide. Founded in 1984 and publicly listed since 1996 on the NYSE (QGEN) and Frankfurt Stock Exchange, the company serves clinical diagnostic laboratories, pharmaceutical and biotechnology companies, forensic and public safety agencies, and academic and research institutions through a portfolio spanning nucleic acid extraction, digital PCR, syndromic infectious disease testing, latent TB detection, and clinical genomics bioinformatics.

The company's portfolio is built around integrated instrument platforms including QIAsymphony Connect, QIAcuity digital PCR (over 3,200 cumulative placements worldwide), QIAstat-Dx syndromic testing, Rotor-Gene Q MDx, and the QIAcuityDx clinical digital PCR system. These are layered with a deep consumables catalogue — QIAamp DSP, RNeasy DSP, EZ1 DSP, QIAwave, QIAseq NGS library prep kits — that drives recurring revenue from installed instruments, plus the QuantiFERON-TB Gold Plus IGRA test serving a 75-million test annual latent TB market. The QIAGEN Digital Insights bioinformatics franchise integrates NVIDIA BioNeMo for graph-based AI over biomedical knowledge graphs, and includes Genoox for AI-powered variant interpretation following the 2025 acquisition. Recent launches include QIA Agent (an AI conversational assistant), QIAsymphony Connect, and QIAcuity gene expression portfolio expansions, supported by strategic M&A in Parse Biosciences (single-cell) and Genoox (AI bioinformatics).

Qiagen operates a razor-and-blade model: capital instruments create a recurring consumables annuity tied to testing volumes, layered with bioinformatics subscriptions and service contracts. Commercial reach combines direct enterprise field sales for pharmaceutical companion diagnostics and high-volume clinical accounts, inside sales for mid-market customers, regional distributors, and a 260,000+ registered e-commerce user base. Recent quarterly performance has been pressured by reduced US and Middle East immigration-related TB testing volumes and cautious US life sciences spending, prompting management to cut FY2026 constant-currency revenue growth guidance from at least 5% to approximately 1-2%; the company maintains a debt-free balance sheet with $646.3 million in cash as of Q1 2026.

Name

Qiagen

Legal name

Qiagen N.V.

Website

https://qiagen.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Qiagen N.V. is a Netherlands-incorporated molecular diagnostics and life sciences tools company providing sample preparation instruments, consumables, diagnostic tests, and bioinformatics services for clinical laboratories, pharmaceutical and biotechnology companies, and academic research institutions worldwide.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• Molecular diagnostics
• Sample preparation reagents
• Digital PCR instruments
• Nucleic acid extraction
• Bioinformatics solutions

Headquarters

HQ city

Venlo

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. Consumables and Reagents: Recurring revenue from consumables (extraction kits, PCR assays, reagents) used on installed instrument platforms. Core revenue driver representing the majority of sales tied to testing volumes and sample preparation workflows.
2. Instruments and Automation: Capital equipment sales including QIAsymphony, QIAcuity, QIAstat-Dx, Rotor-Gene Q platforms. Instruments drive consumable adoption and represent initial customer acquisition.
3. Bioinformatics and Digital Services: Software licenses, digital platforms (QIAGEN Digital Insights), and data analysis services. Includes AI-powered tools like QIA Agent and NVIDIA-powered knowledge graph applications for drug discovery.
4. Services and Support: Technical support, training, calibration, and service agreements for instrument maintenance. Revenue from service plans including RGQ MDx Full Agreement.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Qiagen develops, manufactures, and sells technologies and products for preanalytical sample preparation and molecular assay solutions under its Sample to Insight ecosystem. Its portfolio spans automated instrument platforms (QIAcuity digital PCR, QIAsymphony, QIAstat-Dx, Rotor-Gene Q, QIAcuityDx), consumable kits for nucleic acid extraction and purification, regulated diagnostic tests (QuantiFERON-TB, therascreen, ipsogen), and bioinformatics software (QIAGEN Digital Insights with NVIDIA BioNeMo integration) for clinical diagnostics, pharmaceutical research, and academic customers.

Product overview

Qiagen operates as a molecular diagnostics and life sciences tools company organized around its Sample to Insight ecosystem. The portfolio comprises instrument platforms (QIAsymphony Connect, QIAcuity digital PCR system, QIAcuityDx for clinical diagnostics, QIAstat-Dx syndromic testing, Rotor-Gene Q MDx, QIAxcel Connect, TissueLyser III), consumable kits (QIAamp DSP family for viral/DNA purification, RNeasy DSP FFPE Kit, EZ1 DSP Virus Kit, QIAsymphony DSP Virus/Pathogen Kit, QIAwave sustainable kits, QIAseq NGS library prep), diagnostic tests (QuantiFERON-TB Gold Plus, therascreen oncology, ipsogen leukemia), and bioinformatics platforms (QIAGEN Digital Insights with NVIDIA AI integration). Qiagen generates recurring revenue from consumables tied to its installed instrument base, serving clinical diagnostics, pharmaceutical R&D, and academic research laboratories globally.

Differentiator

Problem solved

Functional benefit

Brands

• QIAsymphony Connect: Next-generation platform for automated clinical sample extraction
• QIAcuity
• QIA Agent
• QuantiFERON
• QIAstat-Dx
• therascreen
• ipsogen
• QIAGEN Digital Insights
• BioNeMo (with NVIDIA partnership)

Products and services

• QIAcuity Digital PCR System Scalable nanoplate-based digital PCR platform for research, clinical, and pharmaceutical applications with over 3,200 cumulative instrument placements worldwide, including gene expression assays and high-multiplex probe PCR kits.
• QIAsymphony Connect Next-generation automated IVD nucleic acid extraction platform with enhanced traceability, high nucleic acid yields, and connectivity for modern clinical laboratories.
• QIAstat-Dx Syndromic Testing Syndromic testing platform using multiplex PCR for rapid detection of infectious disease pathogens from a single sample, with FDA-cleared GI panels on the high-throughput QIAstat-Dx Rise platform.
• QuantiFERON-TB Gold Plus Interferon-gamma release assay (IGRA) for detection of latent tuberculosis infection; the leading IGRA test with planned automated workflow targeting 80% hands-on time reduction by late 2027.
• QIAcuityDx FDA-cleared digital PCR system for in vitro diagnostics with fully automated partitioning, thermocycling, and imaging capabilities for oncology clinical testing.
• Rotor-Gene Q MDx IVD-validated real-time PCR instrument with up to 6 channels spanning UV to infrared wavelengths, featuring centrifugal rotary design for thermal and optical uniformity, supporting CE-IVD-marked PCR kits.
• QIAxcel Connect High-resolution gel electrophoresis system with ready-to-use, easy-to-replace gel cartridges, processing up to 96 samples in a single run.
• TissueLyser III Tissue disruption instrument for effective lysing of challenging samples prior to DNA and RNA analysis, supporting downstream analysis workflows.
• QIAamp DSP Virus Kit Silica-based purification kit of viral DNA and RNA from human plasma and serum for in vitro diagnostic use, using vacuum manifold processing with CE/IVD compliance.
• QIAamp DSP DNA Blood Mini Kit Silica-based purification kit of genomic DNA from human whole blood for in vitro diagnostic use, manual or automated on QIAcube Connect MDx, CE/IVD compliant.
• EZ1 DSP Virus Kit Automated purification kit of viral nucleic acids and bacterial DNA from human serum, plasma, CSF, stool, and nasopharyngeal swabs using magnetic-particle technology on EZ2 Connect MDx or EZ1 Advanced XL, CE-IVD marked.
• QIAsymphony DSP Virus/Pathogen Kit Fully automated purification kit of viral nucleic acids and bacterial DNA on QIAsymphony SP, available in Mini (192 preps, 200µl) and Midi (96 preps, up to 1000µl) formats, CE-IVD marked.
• RNeasy DSP FFPE Kit Purification kit of total RNA from formalin-fixed paraffin embedded (FFPE) tissue sections for in vitro diagnostic use, including Deparaffinization Solution and DNase treatment, CE/IVD compliant.
• QIAseq xHYB Viral and Bacterial Panels Hybrid capture-based targeted NGS panels for high-sensitivity detection and sequencing of respiratory viruses, sexually transmitted pathogens, bacterial AMR genes, and adventitious agents.
• QIAseq FastSelect RNA Library Kits Fast RNA-seq library preparation kits with rRNA removal, library prep and data analysis in under 5 hours, part of QIAseq NGS library prep portfolio.
• QIA Agent AI-powered digital assistant providing researchers with conversational interface for experiment planning, product identification, technical documentation access, and order management.
• QIAGEN Digital Insights Bioinformatics business integrating NVIDIA accelerated computing and BioNeMo platform, applying graph-based AI and retrieval over biomedical knowledge graphs for drug discovery, target identification, and biomarker discovery.

Quantifiable outcome

• QIAcuity platform achieved over 3,200 cumulative instrument placements worldwide with 1,100+ scientific publications
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability9 records

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• NVIDIAcoreStrategic or Co-development Partner · 20 May 2026QIAGEN Digital Insights bioinformatics division partnered with NVIDIA to integrate accelerated computing and BioNeMo platform with QIAGEN's curated biomedical knowledge bases. Uses graph-based AI over biomedical knowledge graphs to help pharmaceutical researchers identify disease mechanisms, therapeutic targets, and biomarkers. Initial pilot programs for select pharma and biotech partners.
• InpecocoreStrategic or Co-development Partner · 7 May 2026Partnership with Inpeco for laboratory automation on QIAsymphony Connect platform. Inpeco provides purpose-built automation to integrate with QuantiFERON latent TB testing workflow. Expected to reduce hands-on time by up to 80% and decouple volume growth from staffing requirements.
• DiasorincoreStrategic or Co-development Partner · 7 May 2026Partnership with Diasorin for LIAISON detection systems integration with QuantiFERON latent TB testing. Builds on existing collaboration for automated workflow solutions targeting late 2027 launch.
• Tracer BiotechnologiesminorStrategic or Co-development Partner · 7 May 2026Co-development agreement for molecular diagnostics market expansion. Part of QIAGEN's broader strategy to develop integrated diagnostic solutions.
• Parse BiosciencescoreStrategic or Co-development Partner · 4 November 2025Qiagen announced acquisition of Parse Biosciences as part of strategy to enhance Sample to Insights solutions in molecular biology. Parse provides single cell RNA sequencing technologies that complement Qiagen's existing sample preparation and analysis portfolio.
• Genoox Ltd.coreTechnology or Integration · 1 July 2025QIAGEN acquired Genoox Ltd. in July 2025 to enhance clinical genomics portfolio with AI-powered variant interpretation technology, strengthening QIAGEN Digital Insights bioinformatics offerings.
• GencurixminorGTM or Marketing Partner · 1 January 2025Gencurix signed product development agreements with QIAGEN and Bio-Rad Laboratories in 2025 for co-commercialization discussions and expansion of precision breast cancer diagnostics globally.
• VerogencoreTechnology or Integration · 9 January 2023Qiagen acquired Verogen for $150 million in January 2023. Verogen specializes in next-generation sequencing (NGS) technologies for human identification and forensic investigations, including exclusive distribution rights for sequencing system and access to genealogical database.
• Hamilton CompanycoreTechnology or IntegrationExpanded Hamilton integration for fully automated laboratory workflows with QIAcuity digital PCR platform. Enables automated nanoplate workflows for life sciences and biopharma labs with the platform achieving over 3,200 cumulative placements.

Scale indicators15 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Bio-Rad Laboratories: Direct peer in life science research tools and clinical diagnostics, with overlapping digital PCR (QXDx), qPCR, nucleic acid extraction, and food/clinical testing reagent portfolios that compete head-to-head with QIAcuity, Rotor-Gene Q, and QIAGEN consumables.
• Bio-Techne: Direct peer in research reagents, proteins, and molecular diagnostics (including ExoDx and molecular multiplexing), competing with Qiagen's research consumables, gene expression assays, and oncology diagnostic offerings.
• Revvity (formerly PerkinElmer): Direct peer in life sciences reagents, genomics, and diagnostics, with overlapping nucleic acid extraction, qPCR, and newborn/clinical screening products that compete across QIAGEN's sample prep and diagnostics lines.

Broad incumbents

• Hologic: Broad incumbent in molecular diagnostics (Panther, Aptima, BioFire FilmArray) overlapping with QIAstat-Dx in syndromic infectious disease testing and competing in women's health diagnostics.
• Roche: Global diagnostics leader with cobas PCR systems, companion diagnostics, and digital PCR development (Digital LightCycler) that competes with QIAcuityDx, QuantiFERON, and therascreen franchises in clinical labs.
• Becton, Dickinson and Company (BD): Major diagnostics and life sciences player with BD MAX molecular system, MAX panels, and flow cytometry reagents, competing with QIAstat-Dx syndromic panels and QIAGEN's sample prep in clinical microbiology.
• Agilent Technologies: Broad incumbent in analytical instruments and life sciences (Caliper, Resolution Bioscience, molecular diagnostics), competing with Qiagen in nucleic acid analysis, digital PCR-adjacent workflows, and clinical genomics.
• Thermo Fisher Scientific: Broad incumbent in life sciences and diagnostics with Applied Biosystems qPCR, Ion Torrent sequencing, and extensive clinical diagnostics, overlapping Qiagen's sample prep, PCR, and clinical research portfolios at much larger scale.
• Danaher (Beckman Coulter, Cepheid, Leica Biosystems): Diversified life sciences and diagnostics conglomerate whose Cepheid GeneXpert and Beckman Coulter molecular diagnostics compete directly with QIAstat-Dx syndromic testing and QIAcuityDx in hospital and reference labs.

Emerging players

• Stilla Technologies: Emerging digital PCR player with the naica system competing in research and translational segments where QIAcuity is established, particularly in liquid biopsy and oncology applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/qiagen
• YouTubeyoutube.com/user/QIAGENvideos
• Facebookfacebook.com/qiagen
• LinkedInlinkedin.com/company/qiagen
• Instagraminstagram.com/qiagen

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A32 records

Investments10 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qiagen